FEEDBACK PLC — Regulatory Filings 2018

Apr 16, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9477K

Feedback PLC

16 April 2018

This announcement contains inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 (MAR).

16 April 2018

Feedback Plc

("Feedback" or the "Company")

Appointment of non-executive director

Cambridge, UK - 16 April 2018: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces the appointment of Simon Sturge as Non-Executive Director with immediate effect.

Mr Sturge joined Merck Healthcare in 2014 and is currently Chief Operating Officer and member of the Healthcare Executive Committee.  He is an experienced healthcare executive in the UK and has built a very strong reputation not only in the biotechnology industry but also in the investment community.  His experience includes eight years at Celltech, and he was the founder and CEO of RiboTargets which later reversed into Vernalis Plc.  After serving as CEO of OctoPlus N.V. for two years, he became Senior Vice President of Boehringer Ingelheim's Biopharmaceutical Business.  Mr Sturge is a regular speaker at conferences including the World Economic Forum.

Dr Alastair Riddell, Chairman of Feedback, said: "Since joining Feedback I have been impressed by the potential of its products in improving patient management. As the Company transforms into a unified structure with a focus on commercial development, it will benefit greatly from the vision, experience and breadth of reach of Simon in the healthcare field to help realise its full potential."

Simon Sturge, Non-Executive Director of Feedback, commented: ""I am very excited to have the opportunity to join the Board of Feedback.  We see that in many fields of healthcare there is substantial value in being a depositary of a large volume of data and even more value in being able to intelligently interpret such data.  I truly feel that textural mapping of tumours will have a significant impact on the way we undertake the development of new pharmaceutical products to increase focus toward personalised treatments as well as improving the diagnosis and treatment of cancer.  I believe that Feedback has an advantage in being an early mover in this field and look forward to taking on an active role as a non-executive director in shaping this next stage in the Company's development."

Regulatory Disclosures

In accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies, Simon John Sturge, aged 59 is, or has been within the last five years, a director or partner in the following companies and partnerships:

Current directorships and partnerships	Past directorships and partnerships held within the last five years
Cristal Therapeutics BV	Silence Therapeutics plc

Simon Sturge currently holds 6,000,000 ordinary shares in the Company, equivalent to 2.13 per cent of the Company's total issued ordinary share capital.

There is no other information required to be disclosed under the AIM Rules for Companies.

Notes to editors

About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.

For further information, please contact:

Feedback plc David Crabb, Chief Executive Officer Lara Mott, Investor Relations	Tel: 01954 718072 IR@fbk.com
Allenby Capital Limited (Nominated Adviser and Joint Broker) David Worlidge / Asha Chotai	Tel: 020 3328 5656
Northland Capital Partners Ltd (Joint Broker) David Hignell / John Howes	Tel: 020 3861 6625
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey	Tel: 020 7469 093

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAIAMLTMBIBBBP